Coherus Appoints Juliana M. Reed, Vice President, Government Affairs

REDWOOD CITY, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today is pleased to announce the appointment of Juliana M. Reed as Vice President, Government Affairs. Ms. Reed joins Coherus with over 10 years in government affairs, specializing in global biosimilars policy.

"We welcome Juliana to the Coherus team," said Denny Lanfear, President and Chief Executive Officer of Coherus. "Juliana is an accomplished executive who brings a wealth of experience, insight and leadership in the development of government policies that impact this new industry. The Coherus leadership team is composed of successful veterans who have helped pioneer the biologics industry. With the addition of Juliana, we now have one of the recognized leading experts on global biosimilar public policy. We look forward to working with Juliana in our efforts towards bringing affordable medications to patients and creating a vibrant marketplace for biosimilars in the US."

"I am thrilled to join Coherus," said Ms. Reed. "The team is driven by a common mission and passion to expand patient access to important medicines by developing biosimilars to biologics that have been on markets for years. It is an honor and a privilege to join them on this mission."

Ms. Reed has extensive experience in governmental and public affairs in the healthcare, pharmaceutical and medical device industries, including roles with Baxter and Hospira. Juliana led the development and execution of the Hospira global biosimilars public policy strategy for the last 10 years, prior to the recent Pfizer acquisition of Hospira. Juliana is the current President of the Biosimilars Forum, a not for profit group representing the US biosimilars industry. The members of the Biosimilars Forum represent the largest pipeline of biosimilars in development in the US. Juliana earned her BS from Marquette University and her MS from DePaul University.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit

CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.